tetano
Editor, Senior Moderator
Microb Cell Fact
. 2024 Feb 6;23(1):41.
doi: 10.1186/s12934-024-02320-5. Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19
Norma A Valdez-Cruz[SUP] 1 2 [/SUP], Diego Rosiles-Becerril[SUP] 3 [/SUP], Constanza E Martínez-Olivares[SUP] 3 [/SUP], Enrique García-Hernández[SUP] 4 [/SUP], Laura Cobos-Marín[SUP] 5 [/SUP], Daniel Garzón[SUP] 6 [/SUP], Francisco E López-Salas[SUP] 3 [/SUP], Guadalupe Zavala[SUP] 7 [/SUP], Axel Luviano[SUP] 8 [/SUP], Alejandro Olvera[SUP] 9 [/SUP], Alejandro Alagón[SUP] 9 [/SUP], Octavio T Ramírez[SUP] 9 [/SUP], Mauricio A Trujillo-Roldán[SUP] 10 11 [/SUP]
Affiliations
Background: Developing effective vaccines against SARS-CoV-2 that consider manufacturing limitations, equitable access, and acceptance is necessary for developing platforms to produce antigens that can be efficiently presented for generating neutralizing antibodies and as a model for new vaccines.
Results: This work presents the development of an applicable technology through the oral administration of the SARS-CoV-2 RBD antigen fused with a peptide to improve its antigenic presentation. We focused on the development and production of the recombinant receptor binding domain (RBD) produced in E. coli modified with the addition of amino acids extension designed to improve antigen presentation. The production was carried out in shake flask and bioreactor cultures, obtaining around 200 mg/L of the antigen. The peptide-fused RBD and peptide-free RBD proteins were characterized and compared using SDS-PAGE gel, high-performance chromatography, and circular dichroism. The peptide-fused RBD was formulated in an oil-in-water emulsion for oral mice immunization. The peptide-fused RBD, compared to RBD, induced robust IgG production in mice, capable of recognizing the recombinant RBD in Enzyme-linked immunosorbent assays. In addition, the peptide-fused RBD generated neutralizing antibodies in the sera of the dosed mice. The formulation showed no reactive episodes and no changes in temperature or vomiting.
Conclusions: Our study demonstrated the effectiveness of the designed peptide added to the RBD to improve antigen immunostimulation by oral administration.
. 2024 Feb 6;23(1):41.
doi: 10.1186/s12934-024-02320-5. Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19
Norma A Valdez-Cruz[SUP] 1 2 [/SUP], Diego Rosiles-Becerril[SUP] 3 [/SUP], Constanza E Martínez-Olivares[SUP] 3 [/SUP], Enrique García-Hernández[SUP] 4 [/SUP], Laura Cobos-Marín[SUP] 5 [/SUP], Daniel Garzón[SUP] 6 [/SUP], Francisco E López-Salas[SUP] 3 [/SUP], Guadalupe Zavala[SUP] 7 [/SUP], Axel Luviano[SUP] 8 [/SUP], Alejandro Olvera[SUP] 9 [/SUP], Alejandro Alagón[SUP] 9 [/SUP], Octavio T Ramírez[SUP] 9 [/SUP], Mauricio A Trujillo-Roldán[SUP] 10 11 [/SUP]
Affiliations
- PMID: 38321489
- DOI: 10.1186/s12934-024-02320-5
Background: Developing effective vaccines against SARS-CoV-2 that consider manufacturing limitations, equitable access, and acceptance is necessary for developing platforms to produce antigens that can be efficiently presented for generating neutralizing antibodies and as a model for new vaccines.
Results: This work presents the development of an applicable technology through the oral administration of the SARS-CoV-2 RBD antigen fused with a peptide to improve its antigenic presentation. We focused on the development and production of the recombinant receptor binding domain (RBD) produced in E. coli modified with the addition of amino acids extension designed to improve antigen presentation. The production was carried out in shake flask and bioreactor cultures, obtaining around 200 mg/L of the antigen. The peptide-fused RBD and peptide-free RBD proteins were characterized and compared using SDS-PAGE gel, high-performance chromatography, and circular dichroism. The peptide-fused RBD was formulated in an oil-in-water emulsion for oral mice immunization. The peptide-fused RBD, compared to RBD, induced robust IgG production in mice, capable of recognizing the recombinant RBD in Enzyme-linked immunosorbent assays. In addition, the peptide-fused RBD generated neutralizing antibodies in the sera of the dosed mice. The formulation showed no reactive episodes and no changes in temperature or vomiting.
Conclusions: Our study demonstrated the effectiveness of the designed peptide added to the RBD to improve antigen immunostimulation by oral administration.